Bob Nelsen

Re­silience has caught the eye of the Cana­di­an gov­ern­ment, which will in­vest $163M to boost mR­NA pro­duc­tion

Bob Nelsen’s Re­silience, with a mis­sion no less am­bi­tious than rewrit­ing the rules of drug man­u­fac­tur­ing, has raced off to a quick lead with just a year of life un­der its belt. The Cana­di­an gov­ern­ment likes what it sees, and plans to cut a healthy check to boost Re­silience’s Mis­sis­sauga fa­cil­i­ty.

The Cana­di­an Strate­gic In­no­va­tion Fund will spend $163 mil­lion will mod­ern­ize and ex­pand pro­duc­tion ca­pac­i­ty for new tech­nolo­gies such as mR­NA, the key com­po­nent of Pfiz­er/BioN­Tech and Mod­er­na’s vac­cine, at Re­silience’s site. The ex­pan­sion will add 205 new jobs in Mis­sis­sauga at a 136,000-square-foot fa­cil­i­ty that cur­rent­ly pro­vides fill-fin­ish man­u­fac­tur­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.